BenzingaAugust 27, 2026 at 3:05 AM NY8 days ago
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo1 hour ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo1 hour ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo1 hour ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo1 hour ago
Radian (RDN) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo1 hour ago